Access Biotech

Access Biotechnology is the life science investment arm of Access Industries, a privately held multinational industrial group founded by Len Blavatnik. Established in 2019 and led by former Pfizer R&D executive Liam Ratcliffe, the firm manages a multi-billion dollar portfolio of private and public biopharmaceutical companies. Access Biotechnology focuses on transformative therapies for conditions with high unmet needs, investing across all development stages from discovery-stage platforms to late-stage clinical programs. The firm's investment strategy is characterized by a long-term orientation and technical rigor, leveraging a team of MDs and PhDs to support the growth of companies developing novel medicines in oncology, immunology, and rare diseases.